Based on the Merus BV stock forecast from 10 analysts, the average analyst target price for Merus BV is USD 86.37 over the next 12 months. Merus BV’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Merus BV is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Merus BV’s stock price was USD 49.66. Merus BV’s stock price has changed by -8.88% over the past week, -4.81% over the past month and +105.63% over the last year.
No recent analyst target price found for Merus BV
No recent average analyst rating found for Merus BV
Company Overview Merus BV
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. Read Less
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with met...Read More
Frequently Asked Questions About Merus BV (MRUS) Stock
Based on ratings from 10 analysts Merus BV's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 19 buy, sell and hold ratings.
Unfortunately we do not have enough data on MRUS's stock to indicate if its a good dividend stock.
Based on targets from 10 analysts, the average taret price for MRUS is USD 86.37 over the next 12 months. The maximum analyst target price is USD 111 while the minimum anlayst target price is USD 61.
Unfortunately we do not have enough data on MRUS's stock to indicate if its overvalued.
The last closing price of MRUS's stock was USD 49.66.
The most recent market capitalization for MRUS is USD 3.42B.
Based on targets from 10 analysts, the average taret price for MRUS is projected at USD 86.37 over the next 12 months.
This means that MRUS's stock price may go up by +73.92% over the next 12 months.
We can't find any ETFs which contains Merus BV's stock.
As per our most recent records Merus BV has 172 Employees.
Merus BV's registered address is Uppsalalaan 17, Utrecht, Netherlands, 3584 CT.
You can get more information about it from Merus BV's website at https://www.merus.nl.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Merus BV (MRUS) Stock
Based on ratings from 10 analysts Merus BV's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 19 buy, sell and hold ratings.
Unfortunately we do not have enough data on MRUS's stock to indicate if its a good dividend stock.
Based on targets from 10 analysts, the average taret price for MRUS is USD 86.37 over the next 12 months. The maximum analyst target price is USD 111 while the minimum anlayst target price is USD 61.
Unfortunately we do not have enough data on MRUS's stock to indicate if its overvalued.
The last closing price of MRUS's stock was USD 49.66.
The most recent market capitalization for MRUS is USD 3.42B.
Based on targets from 10 analysts, the average taret price for MRUS is projected at USD 86.37 over the next 12 months.
This means that MRUS's stock price may go up by +73.92% over the next 12 months.
We can't find any ETFs which contains Merus BV's stock.
As per our most recent records Merus BV has 172 Employees.
Merus BV's registered address is Uppsalalaan 17, Utrecht, Netherlands, 3584 CT.
You can get more information about it from Merus BV's website at https://www.merus.nl.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for MRUS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
